GRIDAI TECHNOLOGIES CORP

GRDXNASDAQ

🏆 #4413 by market capEarnings Aug 17US Equity

$3.29▲ $0.15 (+4.44%)

🌙 After hours$3.29▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 4.4%

7d▲ 19.2%

14d▲ 7.9%

30d▼ 13.4%

1y▲ 82.8%

🏦Market Cap

$22M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $3.24 – $3.32
52-Week Range: $1.08 – $6.93
Volume: $2.12B
Avg Volume: $1.76B
Shares Outstanding: 6.8M
Next Earnings: Oct 22, 2026

Fundamentals Snapshot

Annual Revenue: $36,251
Last Q Revenue: $38,208
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.95
Dividend Yield: —

Why Investors Own GRDX

✓High-growth profile — revenue up +37.3% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$36,251▲ +33.6% YoY

Gross Margin (TTM)

28.0%▲ +2.4% YoY

Operating Income (TTM)

$8,700▲ +33.6% YoY

Free Cash Flow (TTM)

$10,513▲ +33.6% YoY

About GRIDAI TECHNOLOGIES CORP

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

🦦